MEDITE Cancer Diagnostics, Inc. will present at the SeeThruEquity Healthcare Investor Conference on January 11

ORLANDO, Fla., Jan. 7, 2016 (SEND2PRESS NEWSWIRE) — MEDITE Cancer Diagnostics, Inc. (OTC:MDIT / OTCMKTS:MDIT), specializing in the development, manufacturing, and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions announces today that CEO, Michaela Ott and CFO, Robert McCullough will present at the SeeThruEquity First Annual Microcap Healthcare Investor Conference on Monday, January 11, 2016, at the Fairmont San Francisco.